Pure Global AI
NCT05907551Not yet recruiting

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Institut de cancérologie Strasbourg EuropeClinicalTrials.govother
Verified
Study focus
Disease/Condition
Neoplasms
Drug/Device/Intervention
Questionnaires
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Institut de cancérologie Strasbourg Europe
Location
Strasbourg, France
Timeline & enrollment
Phase
N/A
Start date
Jun 30, 2023
End date
Oct 30, 2023
Enrollment
210 participants
Primary outcome

Describe patients' knowledges regarding cutaneous side-effects, nail and hair toxicities induced by anticancer drugs,Describe patients' knowledges regarding dermo-cosmetics and aesthetic solutions that can attenuate cutaneous side-effects, nail and hair toxicities induced by anticancer drugs

Summary

Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities.
 When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and
 individual susceptibility. Although these dermatological adverse events are rarely serious,
 they can significantly alter patients' quality of life, and may even necessitate the
 introduction of curative treatment.
 
 The impact of these side effects can be mitigated by the use of dermo-cosmetic products and
 aesthetic solutions. However, most of this supportive care is not reimbursed by the health
 insurance system, representing a source of inequalities in access to healthcare for cancer
 patients.

ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05907551
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05907551 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut de cancérologie Strasbourg Europe and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.